MedPath
FDA Approval

Bacitracin Zinc and Polymyxin B Sulfate

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
February 27, 2024
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Bacitracin(500 [USP'U] in 1 g)
Polymyxin B(10000 [USP'U] in 1 g)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Preferred Pharmaceuticals Inc.

791119022

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Preferred Pharmaceuticals Inc.

Preferred Pharmaceuticals Inc.

Preferred Pharmaceuticals Inc.

791119022

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Bacitracin Zinc and Polymyxin B Sulfate

Product Details

NDC Product Code
68788-7599
Application Number
ANDA064046
Marketing Category
ANDA (C73584)
Route of Administration
OPHTHALMIC
Effective Date
February 27, 2024
Code: 89Y4M234ESClass: ACTIMQuantity: 500 [USP'U] in 1 g
Code: 19371312D4Class: ACTIMQuantity: 10000 [USP'U] in 1 g
PETROLATUMInactive
Code: 4T6H12BN9UClass: IACT
MINERAL OILInactive
Code: T5L8T28FGPClass: IACT

Drug Labeling Information

Complete FDA-approved labeling information including indications, dosage, warnings, contraindications, and other essential prescribing details.

DESCRIPTION SECTION

DESCRIPTION

Bacitracin zinc and polymyxin B sulfate ophthalmic ointment, USP is a sterile antimicrobial ointment formulated for ophthalmic use.

Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the licheniformis group of Bacillus subtilis var Tracy. It has a potency of not less than 40 bacitracin units/mg. The structural formula for bacitracin A is:

bacitracinchemstructure

Polymyxin B sulfate is the sulfate salt of polymyxin B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units/mg, calculated on an anhydrous basis. The structural formulae are:

polychemstructure

Each gram contains: Actives: bacitracin zinc equal to 500 bacitracin units and polymyxin B sulfate equal to 10,000 polymyxin B units;Inactives: mineral oil and white petrolatum.

CLINICAL PHARMACOLOGY SECTION

CLINICAL PHARMACOLOGY

Polymyxin B sulfate attacks gram-negative bacilli, including virtually all strains of Pseudomonas aeruginosa and Haemophilus influenzae species.

Bacitracin is active against most gram-positive bacilli and cocci including hemolytic streptococci.


INDICATIONS & USAGE SECTION

INDlCATlONS AND USAGE

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin B sulfate.

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION

Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.

FOR OPHTHALMIC USE ONLY


CONTRAINDICATIONS SECTION

CONTRAINDICATIONS

This product is contraindicated in those individuals who have shown hypersensitivity to any of its components.

WARNINGS SECTION

WARNINGS

Ophthalmic ointments may retard corneal healing.


ADVERSE REACTIONS SECTION

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


SPL UNCLASSIFIED SECTION

PRECAUTIONS

As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. Appropriate measures should be taken if this occurs.


© Copyright 2025. All Rights Reserved by MedPath